Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study

The Lancet Oncology - Tập 19 Số 5 - Trang 649-659 - 2018